Clinical Trial Update: Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating mesenchymal stem cell infusions from Wharton’s jelly for COVID-19 related ARDS has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Acute Respiratory Distress Syndrome

Drugs mentioned

• Mesenchymal stem cells from Wharton’s jelly (mesenchymal stem cells from Wharton’s jelly)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: COVID19 ARDS | Phase 2 | Status: COMPLETED